FTC Complaint against Unither
UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION In the Matter of UNITHER PHARMA, INC., and UNITED THERAPEUTICS CORPORATION. DOCKET NO. COMPLAINT The Federal Trade Commission, having reason to believe that Unither Pharma, Inc., a corporation, and United Therapeutics Corporation, a corporation, have violated the provisions of the Federal Trade Commission Act, and it appearing to the Commission that this proceeding is in the public interest, alleges: 1. a. Respondent Unither Pharma, Inc. (“Unither Pharma”) is a Delaware corporation with its principal office or place of business at 1110 Spring St., Silver Spring, Maryland 20910. Unither Pharma is a wholly owned subsidiary of Unither Pharmaceuticals, Inc., which is wholly owned by respondent United Therapeutics Corporation. Unither Pharma markets and sells an L-arginine-based dietary supplement and a …
Continue Reading >FTC Consent Agrement with Unither Pharma
In 2003, Unither Pharma, Inc. and United Therapeutics Corporation settled Federal Trade Commission charges that they made deceptive claims in advertising for their HeartBar products. The companies represented that HeartBar—a chewy food bar and powder containing the amino acid L-Arginine—reduces the risk of developing heart disease, reverses damage to the heart, reduces or eliminates heart disease patients? need for surgery and medications, and substantially decreases leg pain in people with cardiovascular disease. The FTC charged that these claims were not supported by scientific evidence. The consent agreement, shown below, prohibits the defendants from repeating these type of claims for HeartBar and other L-Arginine products unless they have adequate scientific support. It also bars them from making any unsubstantiated claims about the health benefits, performance, or …
Continue Reading >
